Chimeric Licenses Viral Vector Technology from University of Pennsylvania for CDH17 Car T Program

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies.

Under the amended agreement, Chimeric has acquired a non-exclusive know-how license to use Penn’s third-generation lentiviral vector plasmid system for the development and commercialization of CHM 2101 (CDH17 CAR T). Viral vector is a critical component used in the manufacturing of CAR T cells, and third-generation lentiviral vectors offer improved safety over earlier generations1.

The amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its planned phase 1 study of CHM 2101 (CDH17 CAR T) for gastrointestinal cancers.

In addition, Chimeric is able to cross-reference regulatory information on file with the US FDA to facilitate filing of an Investigational New Drug (IND) for CHM 2101.

Under the original license agreement in July 2021, Chimeric acquired the exclusive rights to develop and commercialize certain CDH17 CAR T cell therapies licensed from Penn.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.
1. Milone, M.C., O’Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529–1541 (2018).